痛风石影响问卷(TIQ-20)在降尿酸治疗期间对变化的反应性
研究分析了一项为期2年的别嘌醇剂量递增达标治疗血尿酸临床试验数据,纳入58例有痛风石且基线、第1年和第2年均有TIQ-20评分的患者(其中39例有双能CT数据)。结果显示TIQ-20评分从基线3.59(1.77)降至2.46(1.73),P<0.0001,2年变化均值为-1.13(95%CI -1.54,-0.71),提示TIQ-20是反应性良好的痛风石影响患者报告工具。
要点
- 在有痛风石且接受别嘌醇达标治疗血尿酸的患者中,TIQ-20评分2年内从3.59降至2.46,变化均值-1.13(95%CI -1.54,-0.71),P<0.0001。
- 2年内TIQ-20变化的效应量(Cohen's d)为0.71,高于双能CT尿酸体积的0.50和索引痛风石直径和的0.68。
- 所有痛风石指标在2年期间均观察到改善,TIQ-20是反应性良好的痛风石影响患者报告工具。
核心结论
- 对于接受别嘌醇达标治疗血尿酸的痛风石患者,TIQ-20评分出现改善,同时体格检查和影像学痛风石指标也改善,表明TIQ-20是反应性良好的痛风石影响患者报告工具。
研究设计与样本
- 分析一项为期2年的别嘌醇剂量递增达标治疗血尿酸临床试验数据,纳入有痛风石且基线、第1年和第2年均有TIQ-20评分的患者58例,其中39例有双能CT数据。
- 用游标卡尺测量最多三个索引痛风石的最长直径,并在研究访视时记录TIQ-20;一个研究中心的参与者受邀参加双能CT子研究。
- 数据分析采用重复测量混合模型。
主要发现
- 2年内所有痛风石指标均观察到改善。
- TIQ-20平均(标准差)评分2年内从3.59(1.77)降至2.46(1.73),P<0.0001。
- 2年内TIQ-20变化的均值(95%CI)为-1.13(-1.54,-0.71)。
- 2年内索引痛风石直径和的效应量(Cohen's d)为0.68,双能CT尿酸体积为0.50,TIQ-20为0.71。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In 2015, the 20-item Tophus Impact Questionnaire (TIQ-20) was developed as a tophus-specific patient-reported outcome measure. The aim of this study was to determine whether TIQ-20 scores change during urate-lowering therapy. METHODS: We analysed data from a 2-year clinical trial of allopurinol dose escalation using a treat-to-target serum urate approach. For participants with tophaceous gout, the longest diameter of up to three index tophi was measured, using Vernier calipers, and the TIQ-20 was recorded at study visits. Participants at the one site were invited to participate in a dual-energy CT (DECT) substudy. Participants were included in this analysis if they had tophaceous gout and TIQ-20 scores available at baseline, Year 1 and Year 2 (n = 58, 39 with DECT data). Data were analysed using a mixed-model approach to repeated measures. RESULTS: Improvements were observed in all tophus measures over the 2-year period. The mean (s.d.) TIQ-20 scores reduced over 2 years from 3.59 (1.77) to 2.46 (1.73), P < 0.0001, and the mean (95% CI) TIQ-20 change over the 2 years was -1.13 (-1.54, -0.71). The effect size (Cohen's d) for the change in the sum of the index tophi diameter over 2 years was 0.68, for the DECT urate volume was 0.50, and for the TIQ-20 was 0.71. CONCLUSION: For people with tophaceous gout treated with allopurinol using a treat-to-target serum urate approach, improvements in TIQ-20 occurred, as did improvements in physical and imaging tophus measures. These findings demonstrate that the TIQ-20 is a responsive patient-reported instrument of tophus impact.
引用
- Cao C, Gamble G, Horne A, et al. The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy. Rheumatology (Oxford). 2024. PMID: 37688559. doi:10.1093/rheumatology/kead468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。